Short answer
Emergent BioSolutions Inc. (EBS) filed an 8-K current report with the SEC on September 1, 2026 reporting Item 8.01 (Other Events). BARDA contract modification adds $24 million for additional CYFENDUS anthrax vaccine doses.
Emergent BioSolutions Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- BARDA contract modification adds $24 million for additional CYFENDUS anthrax vaccine doses
- Revenue visibility improves through expanded government procurement under the existing AV7909 contract
- CYFENDUS demand reinforces Emergent’s biodefense portfolio and government customer dependence
- Press release and redacted Modification No. 21 provide detailed commercial terms and timingસ્માત
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Emergent BioSolutions Inc. 8-K filings
Get the next EBS 8-K as it lands
Follow EBS for push alerts, or ask the research agent what this filing means.